Add like
Add dislike
Add to saved papers

Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study.

BACKGROUND: Hidradenitis suppurativa (HS), a chronic, recurrent, debilitating skin disease, is characterized by painful, inflammatory, subcutaneous lesions of the axilla, inguinal, and anogenital regions. Overall prevalence of HS is ~1%, and impact of disease on patient quality of life (QoL) and healthcare resource utilization (HRU) is high.

OBJECTIVES: To estimate the real-world effectiveness of adalimumab (Humira® ) treatment in patients with moderate to severe HS on disease severity, pain, QoL, work productivity, and HRU.

METHODS: HARMONY (Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting) is a multicenter, postmarketing observational study in adult patients with moderate to severe HS. Disease severity and QoL parameters were evaluated using validated measures at 12-week intervals over 52 weeks of treatment. The primary endpoint was the proportion of patients achieving a Hidradenitis Suppurativa Clinical Response (HiSCR: ≥50% reduction in abscess and inflammatory nodule count, with no increase in abscess and draining fistula counts relative to baseline) at 12 weeks. Secondary endpoints were HiSCR at 24, 36, and 52 weeks and changes in QoL parameters and work productivity assessments. Analyses were conducted using as-observed data.

RESULTS: The proportion of patients reaching the primary HiSCR endpoint was 70.2% (n=132/188 enrolled) and remained ≥70% until study completion. There were statistically significant (P<0.0001) reductions in worst and average skin pain. All of the QoL measures evaluated improved significantly (P<0.0001) by 12 weeks of adalimumab treatment, as did work productivity assessments (P<0.05), and there was a ~50% decrease in HRU between baseline and week 52. Adalimumab was well tolerated.

CONCLUSIONS: In this real-world setting, adalimumab treatment of moderate to severe HS resulted in decreased disease severity and improvements in QoL and productivity. Response to adalimumab was rapid (within 12 weeks) and sustained (52 weeks). No unexpected safety signals were reported.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app